AFM
CASC

Anson Funds Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Anson Funds Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-981,428
Closed -$3.65M – 67
2017
Q2 		$3.65M Buy
981,428
+310,499
+46% +$1.23M 1.15% 20
2017
Q1 		$2.78M Buy
670,929
+441,643
+193% +$1.86M 1.15% 19
2016
Q4 		$988K Buy
229,286
+123,003
+116% +$795K 0.31% 34
2016
Q3 		$1.05M Sell
106,283
-43,384
-29% -$308K 0.22% 40
2016
Q2 		$847K Buy
149,667
+35,500
+31% +$241K 0.16% 47
2016
Q1 		$870K Sell
114,167
-23,700
-17% -$182K 0.13% 48
2015
Q4 		$1.84M Buy
+137,867
New +$2.37M 0.59% 34

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

Anson Funds Management's CASC Position: Q3 2017 in Review

Anson Funds Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 981,428 shares — an estimated $3.65M sold.

Anson Funds Management first reported a position in CASC in Q4 2015 and held it in 7 quarters. The position peaked at $3.65M in Q2 2017. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • Anson Funds Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Anson Funds Management sold 981,428 Cascadian Therapeutics, Inc. shares in Q3 2017, an estimated $3.65M.
  • Anson Funds Management first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 7 quarters.
  • Anson Funds Management's Cascadian Therapeutics, Inc. position peaked at $3.65M in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on Anson Funds Management's 13F filing for Q3 2017, filed 14 Nov 2017.